Business
Virios Therapeutics Highlights Safety Data from Phase 2a Fibromyalgia Trial at the International Association for the Study of Pain (IASP) World Congress
ATLANTA--(BUSINESS WIRE)-- Virios Therapeutics, Inc. (Nasdaq: VIRI), a clinical-stage biotechnology company focused on advancing novel antiviral therapies to
About this update from Dogwood Therapeutics, Inc.
[{"type":"text","content":" ATLANTA--(BUSINESS WIRE)--\nVirios Therapeutics, Inc. (Nasdaq: VIRI), a clinical-stage biotechnology company focused on advancing novel antiviral therapies to treat diseases associated with virally triggered or maintained immune responses, announced today that data from the company’s Phase 2a clinical trial PRID-201 demonstrated that IMC-1 was better tolerated than placebo in patients with fibromyalgia (“FM”). This result is highlighted in a poster presentation at the International Association for the Study of Pain (IASP) World Congress, being held virtually June 9 - 11, 2021 and June 16 - 18, 2021.\n\nIMC-1 is a novel, proprietary, fixed dose, antiviral therapy combining famciclovir and celecoxib. This dual mechanism antiviral therapy is designed to synergistically suppress Herpes Simplex Virus-1 (“HSV-1”) activation and replication, with the end goal of reducing viral mediated disease burden.\n\n“There is a clear medical need for new, safe and effective treatments with the potential to improve care for the estimated 10 - 20 million FM patients in the U.S. and more than 200 million worldwide,” commented R. Michael Gendreau, M.D., Ph.D., Chief Medical Officer of Virios Therapeutics. “Our Phase 2a clinical trial data showed that IMC-1 treated patients had higher overall completion rates and lower rates of discontinuation due to adverse events, as compared with placebo-treated patients. This is an especially encouraging result when viewed in the background of current patient and provider dissatisfaction with the generally poor tolerability of existing approved FM treatments,” concluded Dr. Gendreau.\n\nTitle: The Safety of IMC‑1 in Patients with Fibromyalgia: Phase 2a Study Results\n\nLead Author: William Pridgen, M.D., Tuscaloosa Surgical Associates\n\nConclusions: IMC‑1 exhibited an encouraging safety profile, as AEs occurred at a lower rate and were less severe in the IMC‑1 treatment group compared with placebo. The discontinuation rate due to AEs was nearly 3‑fold higher in patients receiving placebo compared with patients receiving IMC‑1, suggesting that treatment with IMC‑1 was unusually well‑tolerated. In this study, IMC‑1 demonstrated significant reductions in pain, fatigue, and other important symptoms in patients with FM. These results suggest that IMC‑1 may offer a promising and well‑tolerated option to treat patients ...